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ABSTRACT 
Objective: Obesity is a chronic disease associated with serious health complications including inflammation, insulin resistance, metabolic 
syndrome, cardiovascular complications and several types of cancers. So this study was carried out to look for effective intervention, especially with 
its rising prevalence in adults and children and lack of well-tolerated therapy. 
Methods: Rats received high-fat diet for four months to induce obesity. Animals which had ≥30 % increase in body weight were selected in this study. 
Obese rats were treated for 8 w with calorie restriction (25 % food restriction of commercial chow) and/or resveratrol (30 mg/kg/day orally). 
Results: Obese rats demonstrated a significant elevation in the body and visceral white adipose tissue (WAT) weight, serum total cholesterol (TC), 
triacylglycerol (TAG) and low-density lipoprotein cholesterol (LDL-c). Visceral WAT gene expression of fatty acid synthase (FAS) significantly 
increased. A remarkable decrease in gene expression of peroxisome proliferator-activated receptor gamma (PPARɣ), lipoprotein lipase (LPL) and 
silent information regulation 2 homolog 1 (Sirt1) was recorded. The combination significantly decreased body and visceral WAT weights, TC, TAG, 
LDL-C and FAS mRNA expression and increased adiponectin level, the mRNA expression of PPARɣ and Sirt1as compared to individual treatments. 
While all treatment strategies showed a similar increase in LPL mRNA expression.  
Conclusion: Calorie restriction supported with resveratrol has beneficial effects in terms of reducing body weight, and appears to reverse high fat 
diet-induced dysregulation of expression of the genes responsible for healthy visceral WAT.  
Keywords: Obesity, Visceral white adipose tissue, Calorie restriction, Resveratrol. 
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INTRODUCTION 
Obesity is a metabolic disease that arises from energy imbalance when 
energy intake exceeds energy expenditure. According to the data from 
the World Health Organization in 2014, 13 % of adults aged ≥18 y old 
were obese, and thus, nearly 2 billion adults worldwide are 
overweight and, of these, more than half a billion are obese[1]. Obesity 
is no longer a cosmetic problem, on the contrary, it is a serious medical 
condition associated with cluster of chronic diseases including, insulin 
resistance, inflammation, type 2 diabetes mellitus, dyslipidemia, 
metabolic syndrome, heart diseases, as well as, several types of 
cancers, so increasing the burden on the society concerning health 
care costs for obesity and its related complications [2, 3].  
White adipose tissue (WAT), was considered in the past as a static 
organ that is hormonally inert and only serves as a site for energy 
storage, however, recently WAT has attracted attention as a dynamic 
organ that represents the largest endocrine organ in the body. The 
WAT is the major source of obesity-related complications, as obesity 
causes WAT hypertrophy, dysregulated expression of several enzymes 
and adipokines e. g. adiponectin and leptin, and elevated expression of 
pro-inflammatory molecules such as TNFα that causes inflammation 
leading to insulin resistance and metabolic. Although both 
subcutaneous and visceral WAT are linked to metabolic risk profile, 
visceral adipose tissue is more associated with metabolic syndrome [4, 
5]. Accordingly our study will focus on the visceral white adipose 
tissue. 
Calorie restriction, defined as reducing caloric intake below usual ad 
libitum intake while maintaining adequate nutrition, represents one 
alternative, and it has been found to extend lifespan in mammals, 
slow aging and reduce the incidence of major diseases like type 2 
diabetes, cardiovascular diseases, and cancer [6]. However, it is 
sometimes difficult to maintain long-term calorie restriction in 
modern society. Consequently, there has been an increased interest 
in developing pharmacological agents that act as calorie restriction 
mimetic as resveratrol (3, 5, 4′ -trans-trihydroxystilbene), naturally 
abundant poly phenolic compound, found in grapes, berries, peanuts 
and red wine [7]. A growing body of literature has provided evidence 
for the multi-faceted properties of resveratrol and suggests that 
resveratrol may have potential therapeutic implications including anti-
inflammatory, antioxidant, cardioprotective, and beneficial properties 
against aging, metabolic diseases and obesity [8, 9]. 
After the withdrawal of sibutramine and rimonabant, as weight loss 
drugs, because the former was found to be associated with increased 
cardiovascular complications and strokes, and the latter; for its 
psychiatric side effects. Orlistat became the only approved drug for 
long-term treatment of obesity which is often not well tolerated for its 
gastrointestinal upsets, and also needs kind of limitation for fat rich 
diets as it prevents dietary fat absorption by only 30 %, thus rises an 
indeed need to have other interventions to obesity management [10].  
Therefore, the present study was undertaken to investigate the 
common therapeutic mechanisms between calorie restriction and 
resveratrol on metabolic changes induced by high-fat diet, and the 
possible synergistic effect of the combination of calorie restriction and 
resveratrol as a promising alternative for obesity management. 
MATERIALS AND METHODS 
Animals and experimental protocol 
Forty mature male wistar albino rats weighing 150±15 g, supplied 
from the Egyptian Organization for Biological Products and Vaccines 
(Cairo, Egypt), were housed in stainless steel rodent cages at room 
temperature (25±2 °C) with a 12 h dark/light cycle. Animals were 
fed rodent chow (El-Nasr Pharmaceuticals and Chemicals Industry, 
Egypt), and allowed free access to drinking water. All animal 
experiments received approval from the Ethical Committee of the 
Faculty of Pharmacy, Zagazig University, Egypt (No. P14/1/2014). 
After one week of acclimatization, rats were assigned to two groups, 
one kept on normal chow diet (n=8) and the other switched to high-
fat diet (25% total fat (including 11% unsaturated fat), 44% 
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carbohydrate, 18% protein, and 13% fiber, ash and other 
ingredients)(n=32) for four months to induce obesity[11]. The latter 
group was subdivided to four groups of eight animals as following: 
obese control group, calorie restricted group (25% food restriction of 
commercial chow), resveratrol (supplied from Mega Resveratrol and 
Candlewood Stars Inc., USA) group (receiving 30 mg/kg daily orally) 
and (calorie restriction+resveratrol) group for 8 w. 
Sample collection and storage 
At the end of the experimental period, body weight was determined 
for all groups then rats fasted overnight, blood was obtained via 
retro-orbital bleeding in dry centrifuge tubes and centrifuged at 
3000 rpm for 15 min for serum separation to analyze biochemical 
parameters, and animals were sacrificed. The visceral white adipose 
tissues were removed and weighed for evaluation of abdominal fat 
content. All tissue samples were frozen until analysis.  
For histological study, visceral fat specimens were kept in 10 % 
formalin for at least 1 w, and then the specimens were dehydrated 
with a series of ascending grade ethanol from 75 to 100 %. Tissues 
were placed thereafter in xylol and embedded in paraffin. Cross 
sections of about 4 µm thickness were processed on slides and 
stained with hematoxylin and eosin (H&E) stain. 
Estimation of biochemical parameters 
Serum levels of TC, TAG and HDL-c, were determined using 
commercially available kits (Spin react), and LDL-c was calculated 
according to Friedewald formula 
LDL-c (mg/dl) = TC–[HDL-c+TAG/5] 
Reverse transcription–polymerase chain reaction 
Total RNA was extracted from visceral white adipose tissue using 
the acid guanidinium thiocyanate–phenol–chloroform method. RNA 
concentration and purity were measured using a UV spectro-
photometer, with A260/A280 ratios of 1.8 to 2.0 considered 
acceptable. Reverse transcription–polymerase chain reaction (RT-
PCR) was performed using the extracted RNA for evaluation of 
PPARɣ, LPL, FAS, and Sirt1 gene expressions. β-actin expression 
level was used as a loading control for each sample. For 
amplification of target genes, RT-PCR was run as 2 separate steps. 
Briefly, equal amounts of total RNA were denatured thermally and 
reverse transcribed using the Moloney murine leukemia virus 
reverse transcriptase (Promega, Madison, Wisconsin), ribonuclease 
inhibitor (Promega), deoxynucleoside 50 triphosphate and oligo-dT 
primer. The reactions were terminated by heating to 95 ᵒC for 10 
min, followed by cooling to 4 ᵒ
 
C. The complementary DNA samples 
were amplified in the presence of Taq DNA polymerase (Promega), 
deoxynucleoside 50 triphosphate, and the appropriate primer pairs 
(primers, annealing temperatures, and product sizes are listed in 
table 1). All PCR products were separated on 2% agarose gels, 
stained with ethidium bromide, and visualized using a UV 
transilluminator. Semi-quantification was performed using a gel 
documentation system (Biodoc analyzer) supplied by Biometra 
(Gottingen, Germany). The relative expression level of each studied 
gene (R) was calculated according to the following formula: R = 
Densitometric units of gene/Densitometric units of β-actin. 
Table 1: Primer sequences, annealing temperature and product size for the studied genes 
Gene Primer sequence Annealing temp. Product size 
PPARγ Forward primer:  
5'-GATGACCACTCCCATTCCTTTG-3' 
Reverse primer:  
5'-GATGCTTTATCCCCACAGACTC-3' 
55 °C 281 bp 
LPL Forward primer:  
5′-GAGATTTCTCTGTATGGCACC-3' 
Reverse primer:  
5′-CTGCAAATGAGACACTTTCTC-3' 
57 °C 275 bp 
Sirt1 Forward primer:  
5′-AGCTGGGGTTTCTGTTTCCT-3' 
Reverse primer:  
5′-TGCTGAGTTGCTGGATTTTG-3' 
55 °C 224 bp 
FAS Forward primer:  
5'-GGCCTGGACTCGCTCATGGG-3' 
Reverse primer:  
5'-TGGGCCTGCAGCTGGGAGCA-3' 
60 °C 514 bp 
Beta actin Forward primer:  
5'-AACCCTAAGGCCAACCGTGAAA-3' 
Reverse primer:  
5'-TCATGAGGTAGTCTGTCAGGTC-3' 
60 °C 265 bp 
Abbreviations: PPARɣ, Peroxisome proliferator-activated receptor gamma; LPL, Lipoprotein lipase; Sirt1, Silent information regulation 2 homolog 1; 
FAS, Fatty acid synthase. 
 
Measurement of adiponectin by enzyme-linked immunosorbent 
assay 
Visceral WAT adiponectin concentrations were measured using an 
enzyme-linked immunosorbent assay (ELISA) kit (In vitro gen) 
according to the manufacturer's instructions. 
Statistical analysis 
All results were expressed as mean±SD. Statistical analysis and 
correlation were performed using GraphPad Prism software. 
Student "t" test and the analysis of variance (one-way ANOVA) 
followed by Tukey’s post hoc test were used for comparison 
between groups. The correlations between the studied 
parameters were assessed using the Pearson's correlation 
coefficient (r).  
RESULTS 
Body and visceral white adipose tissue weights 
Body and visceral WAT weights increased significantly in the obese 
group by 145.5 % and 780.8 % respectively after the four months high 
fat diet compared to the normal group, while significant decreases 
were observed after 8 w in the calorie restriction, resveratrol, and 
calorie restriction+resveratrol groups. The calorie restriction+ 
resveratrol group showed a significant decrease in body and visceral 
WAT weight compared to calorie restriction group (fig. 1A and 1B). 
Serum parameters 
Comparison between normal and obese groups (table 2) has shown 
that the obese group had significantly higher total cholesterol, 
triacylglycerol and LDL-c (p<0.001) and lower levels of HDL-c. These 
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alterations in lipid profile were significantly ameliorated in all 
treated groups. 
Co-administration of resveratrol with calorie restriction significantly 
lowered total cholesterol, triacylglycerol and LDL-c by 17.9 %, 27.5 
%, and 29 % respectively, as compared to calorie restricted group 
(p<0.05). The HDL-c showed non-significant change. 
Tissue parameters 
Messenger RNA expression of PPARɣ, LPL, Sirt1 and FAS in 
visceral WAT 
There was a significant decrease in visceral WAT PPARɣ, LPL, and 
Sirt1 messenger RNA (mRNA) expression with a concomitant 
increase of FAS mRNA expression in obese rats as compared to 
normal (P<0.001). Calorie restriction, RSV and their combination are 
induced a marked up regulation of PPARɣ and LPL genes and 
downregulation of FAS gene. However, CR and its combination with RSV 
showed significant up regulation for Sirt1 gene. In comparison to CR 
group, the combination demonstrated a marked up regulation of PPARɣ 
and Sirt1 genes and downregulation of FAS gene (fig. 2A, 2B,2C and 2D). 
Adiponectin 
Figure3. Illustrate that high-fat diet and subsequent obesity-induced 
a significant decrease in adiponectin content in white adipose tissue 
as compared to the normal control group (p<0.001). Treatment with 
calorie restriction or resveratrol either individually or in 
combination significantly increased adiponectin as compared to the 
obese control group (p<0.05). 
In comparison to CR rats, the combination revealed a significant 
increase in WAT adiponectin content (p<0.05). 
 
 
Fig. 1: Effects of CR, RSV and their combination on Body weight (A) and visceral WAT weight (B); Values are expressed as mean±SD (n=8), 
# significantly different from normal group at p<0.001, *significantly different from obese group at p<0.05, ª significantly different from 
calorie restricted group at p<0.05. CR, calorie restriction; RSV, resveratrol; WAT, White adipose tissue 
 
Table 2: Serum parameters of obese rats with calorie restriction, resveratrol (30 mg/kg/day) either individually or in combination with 
calorie restriction for 8 w 
 Normal Obese CR RSV CR+RSV 
TC 85.4±4.4 145.6±7.2 108.1±10.4* # 109.8±14.5* 88.8±7* ª 
TAG 61.1±4.1 110±9.4 86.8±7* # 73.9±2.8* ª 62.9±8.6* ª 
HDL-C 36.5±4.2 24.3±4.3 35.6±5.6* # 34.2±5.9* 37.1±3.8* 
LDL-C 36.7±1 99.3±1.6 55.1±3.9* # 60.8±9.9* 39.1±1.9* ª 
Values are expressed as mean±SD (n=8), # significantly different from the normal group at p<0.001, * significantly different from the obese group at 
p<0.05, ª significantly different from calorie restricted group at p<0.05. CR, calorie restriction; RSV, resveratrol; TC, total cholesterol; TAG, 
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Fig. 2: Effects of CR, RSV and their combination on mRNA expression of PPARɣ (A), LPL (B), Sirt1 (C) and FAS (D). # Significantly different 
from normal group at p<0.001,* Significantly different from obese group at p<0.05,ª Significantly different from calorie restricted group 
at p<0.05, CR, calorie restriction; RSV, resveratrol; PPARɣ, Peroxisome proliferator-activated receptor gamma; LPL, Lipoprotein lipase; 
Sirt1, Silent information regulation 2 homologs 1; FAS, Fatty acid synthase 
 
 
Fig. 3: Effects of CR, RSV and their combination on Adiponectin 
concentration. Values are expressed as mean±SD (n=6), # 
significantly different from the normal group at p<0.001, 
*significantly different from the obese group at p<0.05, ª 
significantly different from calorie restricted group at p<0.05. CR, 




Fig. 4: A photomicrograph of sections in visceral WAT (H&E 
X100) from different groups showing many adipocytes with 
very big size in obese rats, and smaller size in CR, RSV and their 
combination. CR, calorie restriction; RSV, resveratrol 
 
Fig. 5: Correlation between visceral WAT LPL gene expression 
and visceral WAT PPARγ gene expression. WAT, white adipose 
tissue; PPAR gamma, Peroxisome proliferator-activated 
receptor gamma; LPL, Lipoprotein lipase 
 
 
Fig. 6: Correlation between visceral WAT PPARγ gene 
expression and visceral WAT adiponectin level. WAT, white 
adipose tissue; PPAR gamma, Peroxisome proliferator-
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Fig. 7: Correlation between serum HDL-C and visceral WAT 
adiponectin level. WAT, white adipose tissue; HDL-c, high-
density lipoprotein cholesterol 
 
 
Fig. 8: Correlation between serum TAG and visceral WAT 
adiponectin level. WAT, white adipose tissue; TAG, triacylglycerol 
 
 
Fig. 9: Correlation between serum LDL-C and visceral WAT 
adiponectin level. WAT, white adipose tissue; LDL-c, low-
density lipoprotein cholesterol 
 
The morphological changes in visceral WAT 
Microscopic examination of H&E stained sections of visceral WAT of 
the normal group revealed small size adipocytes. However, the 
obese group showed extremely enlarged adipocytes. 
All strategies of treatment either dietary (CR) or therapeutic 
(Resveratrol) or combination showed an observed decrease in the 
size of adipocytes, relatively similar to that of normal rats. 
DISCUSSION 
The present study provides some evidence for a high fat diet-induced 
metabolic disturbances and protective effect of maintaining negative 
energy balance through calorie restriction or administration of 
resveratrol (30 mg/kg/day), as well as, their combination. 
The current work handled the effect of high-fat diet in the induction 
of obesity. The latter was manifested in a marked increase in body 
weight and visceral WAT mass. Moreover, dyslipidemia was 
reported with a dramatic increase in serum TC, TAG and LDL-c and 
decrease in HDL-c. 
Additionally, the study demonstrated a significant reduction in 
visceral WAT mRNA expression of PPARγ and LPL in obese rats 
compared to normal one which, in part, could be explained by the 
increase of inflammatory mediators associated with obesity 
including TNFα, leading to CCAAT interactions with PPARγ and LPL 
promoter regions. Our results are in good accordance with those 
published by other authors [12, 13]. Moreover, this study showed a 
positive correlation between PPARγ and LPL. This result is in 
consistency with another study [14]and this provides evidence that 
LPL gene is a target for the action of PPARγ. 
The study presented here stated a significant reduction in adiponectin 
level in obese rats compared to normal one. Large adipocytes found in 
obese rats are known to produce higher levels of pro-inflammatory 
cytokines including TNFα, these inflammatory cytokines, and hypoxia 
that results in endoplasmic reticulum stress due to the accumulation 
of unfolded proteins in the endoplasmic reticulum can induce a 
reduction in adiponectin level [15, 16]. In addition decrease in PPARγ, 
which is involved in enhancing adiponectin levels through 
endoplasmic reticulum oxidoreductase (Erol-Lα) and disulfide-bond A 
oxidoreductase-like protein (DsbA-L), could contribute to this 
reduction[17]. This study clearly demonstrated a positive correlation 
between PPARγ and adiponectin. 
Our data suggested the presence of insulin resistance state which 
has been previously reported being associated with decreased 
expression of PPARγ, LPL and adiponectin [18-20]. 
With regard to FAS, the central enzyme in de novo lipogenesis, the 
present study showed a significant rise in its visceral WAT 
expression in high-fat diet supplemented rats, which is significantly 
related to obesity and visceral fat accumulation. 
The Sirt1, a nicotinamide adenine dinucleotide (NAD P+ P) dependent 
protein deacetylase causing either activation or inactivation of 
target proteins, has been extensively studied for its multiple 
beneficial effects including anti-obesity effect through decreasing 
adipogenesis and lipogenesis and increasing mitochondrion genesis 
[21]. In the present study, it was found that high-fat diet significantly 
downregulates the expression of Sirt1 in visceral WAT. 
Both consumptions of calorie restricted diet and resveratrol showed a 
significant increase in mRNA expression of PPARγ and consequently 
LPL as one of its target genes and thus protect from many detrimental 
effects of obesity. This action is obtained through maintaining the 
differentiated state of adipocytes and the growing number of small 
adipocytes resulting in increasing insulin sensitivity, and possibly by 
causing apoptosis of large fat cells [22, 23]. 
Adiponectin, which is a protein greatly expressed by adipose tissue 
and involved in lipid metabolism by increasing fatty acids oxidation 
and lowering free fatty acids, has an anti-obesity activity possibly 
through activation of AMPK and PPARα pathways[24]. Adiponectin 
was significantly increased in CR and resveratrol groups 
contributing to their body weight-lowering effects and causing 
metabolic improvements by reducing serum TAG and fat cell size. 
Another possible mechanism for the action of adiponectin proposed 
by [25] is decreasing the secretion of tissue inhibitor of 
metalloproteinase (TIMP), essential for adipogenesis, thus reducing 
adipocyte hypertrophy and fat accumulation. 
As a result of the significant increase in gene expression of genes 
related to lipid processing in adipose tissue as LPL and the 
significant increase in adiponectin level, in which its subnormal 
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levels are known to be related to dyslipidemia [26], an improvement 
of the lipid profile represented by significant decrease in serum 
levels of TC, TAG, LDL-c with a significant increase in HDL-c was 
observed in treated rats. These results were supported by 
correlation studies. 
Beneficial effects of CR in the protection against diet-induced obesity 
and its adverse consequences as insulin resistance can also be 
attributed to the significant increase in visceral WAT expression of 
Sirt1. This effect may be through several proposed mechanisms 
including de acetylation and activation ofPGC-1α, a master regulator 
of mitochondrial biogenesis and fatty acid oxidation and could 
promote energy expenditure[27]. De acetylation and activation of 
FoxO1 that up-regulates adipose triglyceride lipase (ATGL) which 
activates lipolysis in adipocytes and reduces TAG stores[28], and by 
reducing the expression of lipogenic enzymes [29]. 
By contrast to some publications that stated sirt1 activation as one 
mechanism by which resveratrol produces its beneficial effects on 
health[30-32], our results showed that resveratrol alone exert only 
weak non-significant increase in sirt1 expression, while upon 
combining with CR, a sirt1 activator, this group expressed a 
significant increase when compared with both obese and CR groups. 
Growing evidence has proposed that resveratrol treatment mimics CR 
in numerous health aspects, including its metabolic effects [6, 33]. 
The present study shed light on the beneficial effects of using a 
combination between CR and resveratrol compared to CR alone. The 
results demonstrated a synergistic effect for this combination 
represented as a significant decrease in body weight, visceral WAT 
weight, and adipocyte size in the group receiving CR+resveratrol 
when compared to the group on CR alone. 
Additionally, better improvement in the lipid profile, significant 
increase in visceral WAT mRNA expression of PPARγ, Sirt1 and 
levels of adiponectin and significant decrease in visceral WAT mRNA 
expression of FAS were observed in the group receiving 
CR+resveratrol, when compared to the group on CR alone. 
CONCLUSION 
Dietary treatment of obesity by restricting calorie intake can suppress 
body weight gain and improve the metabolic effects caused by obesity. 
Antioxidant, anticancer and cardioprotective effect of resveratrol (as 
therapeutic treatment of obesity) can potentiate the favorable effect of 
CR diet. Therefore, this study recommended such regimens especially 
the combination to reduce adverse metabolic syndrome of obesity. 
Further clinical studies are an urgent need to validate these results. 
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